Australian Clinical Labs Limited (ASX:ACL – Get Free Report) declared a interim dividend on Wednesday, March 27th, MarketIndexAU reports. Investors of record on Thursday, April 25th will be paid a dividend of 0.03 per share on Thursday, April 25th. This represents a yield of 1.1%. The ex-dividend date is Wednesday, March 27th.
Australian Clinical Labs Price Performance
The company has a quick ratio of 0.53, a current ratio of 0.66 and a debt-to-equity ratio of 198.17.
Insider Transactions at Australian Clinical Labs
In other Australian Clinical Labs news, insider Christine Bartlett acquired 20,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were bought at an average cost of A$2.36 ($1.54) per share, for a total transaction of A$47,160.00 ($30,823.53). Corporate insiders own 17.64% of the company’s stock.
Australian Clinical Labs Company Profile
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services.
Further Reading
- Five stocks we like better than Australian Clinical Labs
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How to Invest in Insurance Companies: A Guide
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- The 3 Best Fintech Stocks to Buy Now
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Australian Clinical Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Australian Clinical Labs and related companies with MarketBeat.com's FREE daily email newsletter.
